IQV Valuation Metrics
IQV Stock Price Metrics
IQV Dividend Metrics
IQV Growth Rate Metrics
IQV Discounted Cash Flow Metrics
| Fair Value Price | $265.83 |
| Margin of Safety | 44.96% |
IQV Revenue Metrics
IQV PE Ratio Metrics
| PE Ratio | 22.72 |
| PE Ratio Avg TTM | 25.98 |
| PE Ratio Avg 3Y | 29.31 |
| Current VS TTM Avg | -12.55% |
| Current VS 3Y Avg | -22.47% |
| Current VS 5Y Avg | -40.96% |
IQV PS Ratio Metrics
| PS Ratio | 1.87 |
| PS Ratio Avg TTM | 2.07 |
| PS Ratio Avg 3Y | 2.42 |
| Current VS TTM Avg | -9.48% |
| Current VS 3Y Avg | -22.62% |
| Current VS 5Y Avg | -31.33% |
IQV PB Ratio Metrics
| PB Ratio | 5.01 |
| PB Ratio Avg TTM | 5.40 |
| PB Ratio Avg 3Y | 5.98 |
| Current VS TTM Avg | -7.30% |
| Current VS 3Y Avg | -16.27% |
| Current VS 5Y Avg | -24.55% |
IQV Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 11.65 |
| PFCF Ratio Avg TTM | 13.97 |
| PFCF Ratio Avg 3Y | 20.37 |
| Current VS TTM Avg | -16.60% |
| Current VS 3Y Avg | -42.79% |
| Current VS 5Y Avg | -45.31% |
IQV Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 2.49 |
| Debt/Equity Ratio Avg TTM | 2.41 |
| Debt/Equity Ratio Avg 3Y | 2.34 |
| Current VS TTM Avg | +3.32% |
| Current VS 3Y Avg | +6.52% |
| Current VS 5Y Avg | +10.18% |
IQV PEG Ratio Metrics
| PEG Ratio | 6.34 |
| PEG Ratio Avg TTM | 6.34 |
| PEG Ratio Avg 3Y | 6.34 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | 0.00% |
IQV FCF Yield
| FCF Yield | 8.58% |
| FCF Yield Avg TTM | 7.33% |
| FCF Yield Avg 3Y | 5.49% |
| Current VS TTM Avg | +17.03% |
| Current VS 3Y Avg | +56.27% |
| Current VS 5Y Avg | +69.23% |
IQV Earnings Yield
| Earnings Yield | 4.40% |
| Earnings Yield Avg TTM | 3.95% |
| Earnings Yield Avg 3Y | 3.55% |
| Current VS TTM Avg | +11.39% |
| Current VS 3Y Avg | +23.93% |
| Current VS 5Y Avg | +45.69% |
IQV EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 13.56 |
| Ev/Ebit Ratio Avg TTM | 20.40 |
| Ev/Ebit Ratio Avg 3Y | 24.04 |
| Current VS TTM Avg | -33.52% |
| Current VS 3Y Avg | -43.59% |
| Current VS 5Y Avg | -54.86% |
IQV EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 8.90 |
| Ev/Ebitda Ratio Avg TTM | 13.19 |
| Ev/Ebitda Ratio Avg 3Y | 14.98 |
| Current VS TTM Avg | -32.52% |
| Current VS 3Y Avg | -40.57% |
| Current VS 5Y Avg | -47.92% |
IQV EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.05 |
| Ev/Assets Ratio Avg TTM | 1.56 |
| Ev/Assets Ratio Avg 3Y | 1.81 |
| Current VS TTM Avg | -32.88% |
| Current VS 3Y Avg | -42.08% |
| Current VS 5Y Avg | -47.09% |
IQV EV/Sales Ratio Metrics
| Ev/Sales Ratio | 1.88 |
| Ev/Sales Ratio Avg TTM | 2.83 |
| Ev/Sales Ratio Avg 3Y | 3.22 |
| Current VS TTM Avg | -33.65% |
| Current VS 3Y Avg | -41.61% |
| Current VS 5Y Avg | -46.78% |
IQV Current Ratio Metrics
| Current Ratio | 0.75 |
| Current Ratio Avg TTM | 0.79 |
| Current Ratio Avg 3Y | 0.83 |
| Current VS TTM Avg | -5.66% |
| Current VS 3Y Avg | -10.18% |
| Current VS 5Y Avg | -16.20% |
IQV Quick Ratio Metrics
| Quick Ratio | 0.75 |
| Quick Ratio Avg TTM | 0.79 |
| Quick Ratio Avg 3Y | 0.83 |
| Current VS TTM Avg | -5.66% |
| Current VS 3Y Avg | -10.18% |
| Current VS 5Y Avg | -16.20% |
IQV ROIC Metrics
| ROIC | 8.23% |
| ROIC Avg 3Y | 8.23% |
| ROIC Avg 5Y | 6.99% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | +17.68% |
| Current VS 10Y Avg | +27.08% |
IQV Return on Assets Metrics
| ROA | 4.54 |
| ROA Avg TTM | 4.82 |
| ROA Avg 3Y | 4.76 |
| Current VS TTM Avg | -5.81% |
| Current VS 3Y Avg | -4.62% |
| Current VS 5Y Avg | +13.08% |
IQV Return on Equity Metrics
| ROE | 20.91 |
| ROE Avg TTM | 21.77 |
| ROE Avg 3Y | 21.17 |
| Current VS TTM Avg | -3.95% |
| Current VS 3Y Avg | -1.23% |
| Current VS 5Y Avg | +19.12% |
IQV Net Profit Margin Metrics
| Net Profit Margin | 8.34% |
| Net Profit Margin Avg TTM | 8.63% |
| Net Profit Margin Avg 3Y | 8.47% |
| Current VS TTM Avg | -3.30% |
| Current VS 3Y Avg | -1.53% |
| Current VS 5Y Avg | +15.57% |
Last Updated: Wednesday, June 10, 2026
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib